Related Experiment Video
Updated: May 13, 2025

03:50
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
1.6K
Non-Invasive Auricular Acupoint Stimulation Improves Slow-Transit Constipation: Evidence From a Randomized Controlled
Summary
Non-invasive auricular acupoint stimulation combined with prucalopride significantly improved slow-transit constipation symptoms. This approach offers a promising complementary therapy for managing constipation effectively.
Area of Science:
- Gastroenterology
- Neuromodulation
- Complementary Medicine
Background:
- Slow-transit constipation (STC) lacks effective treatments due to adverse effects and limited efficacy of current therapies.
- Auricular acupoint stimulation (AAS) presents a potential neuromodulatory adjunctive approach for STC, but its clinical utility is unproven.
Purpose of the Study:
- To evaluate the efficacy of non-invasive auricular acupoint stimulation (AAS) as an adjunct to prucalopride for treating slow-transit constipation (STC).
- To investigate the mechanistic role of AAS in modulating gastrointestinal function and symptom scores in STC patients.
Main Methods:
- Sixty STC patients (40-75 years) were randomized into two groups: study (AAS + prucalopride) and control (prucalopride monotherapy).
- Interventions were assessed by monitoring serum neuropeptide Y (NPY), nitric oxide (NO), fecal water content, and gastrointestinal transit time.
- Symptom scores were used to determine comparative therapeutic outcomes.
Main Results:
- The study group achieved a significantly higher overall efficacy rate (93.3%) versus the control group (84.6%, P<0.05).
- Both groups showed reduced NPY and NO levels, with increased fecal water content and colonic transit.
- The AAS group demonstrated more significant reductions in NPY/NO and greater improvements in transit and water content compared to controls (P<0.05).
Conclusions:
- Non-invasive auricular acupoint stimulation significantly enhances symptom relief in patients with slow-transit constipation.
- AAS shows potential as an effective complementary therapy for constipation management, improving gastrointestinal function markers.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
111
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
111
Drugs for Treatment of Diarrhea-Predominant IBS
124
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
124

